610 Medizin und Gesundheit
Refine
Year of publication
- 2013 (350) (remove)
Document Type
- Article (265)
- Doctoral Thesis (34)
- Conference Proceeding (14)
- Part of Periodical (14)
- Contribution to a Periodical (12)
- Book (3)
- Review (3)
- Part of a Book (2)
- Periodical (2)
- Preprint (1)
Is part of the Bibliography
- no (350)
Keywords
- Video (19)
- Capsule endoscopy (12)
- Small bowel (10)
- Endoscopy (7)
- Balloon enteroscopy (6)
- Enteroscopy (6)
- Endoscopic retrograde cholangiopancreatography (4)
- Apoptosis (3)
- IAP proteins (3)
- Smac (3)
- epigenetics (3)
- Atrial fibrillation (2)
- Begriff (2)
- Begriffsgeschichte <Fach> (2)
- Bile duct stone (2)
- Blog (2)
- Breast cancer (2)
- CBA (2)
- COPD (2)
- Cholangiography (2)
- Cholangiopancreatography (2)
- Colonoscopy (2)
- Colorectal cancer (2)
- Double-balloon enteroscopy (2)
- Endoscopic retrograde (2)
- Enterscopy (2)
- Extended donor criteria (2)
- Gesichtsauflösung (2)
- Hemorrhage (2)
- Herb induced liver injury (2)
- IL-6 (2)
- KGF (2)
- Lymphectasia (2)
- Migration (2)
- PDGFRβ (2)
- ROS (2)
- Rhabdomyosarcoma (2)
- SD-OCT (2)
- Sestrin 2 (2)
- Social Media (2)
- Standard endoscopy (2)
- Stroke (2)
- Thrombolysis (2)
- VEGF (2)
- Web 2.0 (2)
- apoptosis (2)
- cardiac (2)
- cell death (2)
- gamma (2)
- glioblastoma (2)
- immunotherapy (2)
- leukemia (2)
- radiotherapy (2)
- schizophrenia (2)
- signal transduction (2)
- synchrony (2)
- therapy (2)
- ALL (1)
- AML (1)
- Actin (1)
- Adenocarcinoma (1)
- Adhesion (1)
- Adolescence (1)
- Airways (1)
- Allergy (1)
- Angiectasia (1)
- Angiodysplasia (1)
- Antibiotic generic drugs (1)
- Anticoagulation (1)
- Antifungal agents (1)
- Antineoplastic agents (1)
- Antiretrovirals (1)
- Antiviral therapy (1)
- Aortic debranching (1)
- Aortic dissection (1)
- Aromatase inhibitors (1)
- Arteriovenous malformation (1)
- Aspergillosis (1)
- Assessment (1)
- Asthma (1)
- Augenheilkunde (1)
- Augenverletzungen (1)
- Auric nanoparticles (1)
- Autism spectrum disorder (1)
- B-cell (1)
- B16 cells (1)
- BCL2 (1)
- BCR-ABL (1)
- BRVO (1)
- Ballet (1)
- Ballon-assisted enteroscopy (1)
- Bcl-2 (1)
- Befindlichkeit (1)
- Benign disorder (1)
- Bevacizumab (1)
- Bewältigung (1)
- Bildnis (1)
- Billroth II gastroenterostomy (1)
- Billroth papillotome (1)
- Billroth’s operation-II (1)
- Blood-brain barrier (1)
- Bortezomib (1)
- Brain (1)
- Brain development (1)
- Brain repair (1)
- Burnout-Syndrom (1)
- C1-inhibitor deficiency (1)
- CIOMS (1)
- CRVO (1)
- CXCL12 (1)
- CXCR4 (1)
- Cancer (1)
- Cancer stem cells (1)
- Candida (1)
- Capecitabine (1)
- Capsule endoscopy, video (1)
- Cardiac surgery (1)
- Castleman’s disease (1)
- Catheter ablation (1)
- Celiac disease (1)
- Cell Death (1)
- Cell Signaling (1)
- Cell Surface Receptor (1)
- Cellular Immune Response (1)
- Cerasorb (1)
- Cerebral Vasospasm (1)
- Chemoradiotherapy (1)
- Chronic illness (1)
- Chronic obstructive airway disease (1)
- Clip (1)
- Cohort study (1)
- Communication (1)
- Comparative study (1)
- Coordination Of Control Modes (1)
- Core needle biopsy (1)
- Coronary artery disease (CAD) (1)
- Cost And Quality Management (1)
- Crohn’s disease (1)
- Cryoablation (1)
- Cyanoacrylate (1)
- Cytochrome P450 (1)
- Cytokine (1)
- Cytotoxicity (1)
- DNA Adducts (1)
- DR5 (1)
- Dancer (1)
- Delayed Cerebral Ischemia (1)
- Dentin adhesives (1)
- Dermatologie (1)
- Device (1)
- Diabetic nephropathy (1)
- Dieulafoy’s lesion (1)
- Digestive system (1)
- Dilated cardiomyopathy (1)
- Disease management (1)
- Docetaxel (1)
- Doctors In Management (1)
- Double balloon enteroscopy (1)
- Doubling time (1)
- Drug Therapy (1)
- Drug hepatotoxicity (1)
- Drug induced liver injury (1)
- Duodenum (1)
- EEG (1)
- EWS/Fli1 (1)
- Ectopic bone formation (1)
- Ectopic varices (1)
- Effectivity (1)
- Elderly (1)
- Ellipticine (1)
- Endomicroscopy (1)
- Endoscopic papillotomy (1)
- Endoscopic retrograde cholangiography (1)
- Endoscopic sphincterotomy (1)
- Endoscopic treatment (1)
- Endoscopic ultrasound (1)
- Energieumsatz <Medizin> (1)
- Entzündung (1)
- Erschöpfung (1)
- Esophagogastric (1)
- Europe (1)
- European Comparison (1)
- Ewing sarcoma (1)
- Exemestane (1)
- FAP (1)
- FTY720 (1)
- Facet joint osteoarthritis (1)
- Fast-track (1)
- Female (1)
- Fever (1)
- Fibrinolytic (1)
- Fingolimod (1)
- G-CSF (1)
- Gastric adenoma (1)
- Gastric cancer (1)
- Gastritis (1)
- Gastrointestinal bleeding (1)
- Gene polymorphism (1)
- Generic drugs (1)
- Gesicht (1)
- Gesicht <Motiv> (1)
- Gewebedurchblutung (1)
- Gewebetemperatur (1)
- Giant lymph node hyperplasia (1)
- Glivec® (1)
- Glomerulonephritis (1)
- Gold (1)
- Graft function (1)
- Graft survival (1)
- Graz <2013> (1)
- HAE (1)
- HDACi (1)
- HIV therapy (1)
- HNPCC (1)
- HSPC (1)
- Heart (1)
- Hebbian plasticity (1)
- Hematologic malignancies (1)
- Hemobilia (1)
- Hepatitis C (1)
- Herbalife products (1)
- Hexavalent vaccine (1)
- Hormonal (1)
- Hospital Governance (1)
- Hydroxyapatite (1)
- ICU (1)
- IMiD® (1)
- ISO (1)
- Identity (1)
- Identität (1)
- Immunology (1)
- In-vivo (1)
- Infektionsabwehr (1)
- Infektionskrankheit (1)
- Inflammatory bowel disease (1)
- Inflammatory fibroid polyp (1)
- Infrarot (1)
- Innate Immunity (1)
- Innate immunity (1)
- Integrin (1)
- Intestinal fistula (1)
- Intestinal metaplasia (1)
- Intestinal neoplasms (1)
- Invasive candidiasis (1)
- Ischemia (1)
- Ischemia-reperfusion injury (1)
- Kava (1)
- Kidney disease (1)
- Kinderwunsch (1)
- Kommunikation (1)
- Kongress (1)
- Krankheit (1)
- Krankheitsbegriff (1)
- Künste (1)
- Landmark (1)
- Langerhans cell histiocytosis (1)
- Lebensbewältigung (1)
- Lebensgefühl (1)
- Liver biopsy (1)
- Liver histology (1)
- Liver injury (1)
- Liver transplantation (1)
- Lumbar stenosis (1)
- Lung (1)
- Lymphangiectasia (1)
- Lymphoepithelioma (1)
- Lymphoma (1)
- MACE (1)
- MCAO (1)
- MCP (1)
- MCP-1 (1)
- MEG (1)
- MLL (1)
- MTCL (1)
- MTT (1)
- Male (1)
- Marginal grafts (1)
- Medizin (1)
- Medizinische Ausbildung (1)
- Mena/VASP (1)
- Metal clip (1)
- Metapher (1)
- Metastatic (1)
- Mid-intestinal bleeding (1)
- Minimally invasive transforaminal interbody fusion (1)
- Missbildung (1)
- Moderating factors (1)
- Multiple trauma (1)
- Mund-Kiefer-Gesichts-Chirurgie (1)
- Mycoses (1)
- NF-κB (1)
- NK Receptor (1)
- NK cell (1)
- NS3-4A protease inhibitor (1)
- NS5B polymerase inhibitor (1)
- NanoBone (1)
- Nanocrystalline (1)
- Natural Killer (NK) Cell (1)
- Neoadjuvant radiochemotherapy (1)
- Neoadjuvant treatment (1)
- Nerven <Begriff> (1)
- Neural function (1)
- Neural stem cells (1)
- Neurasthenie (1)
- Neuroendocrine tumor (1)
- Neurogenesis (1)
- Neurotransmitter (1)
- New Developments (1)
- Nicht-Ereignis (1)
- Non-Hodgkin lymphoma (1)
- Occupational disease (1)
- Occupational exposure (1)
- Occupational health (1)
- Oesophagogastric cancer oxaliplatin (1)
- Off-pump surgery (1)
- Oncolytic virus (1)
- Oncotargets (1)
- Online-Magazin (1)
- Online-Magazine (1)
- Organ allocation (1)
- Organ rinse (1)
- Organ shortage (1)
- Osteoinduction (1)
- Osteoporosis (1)
- Outcome (1)
- Over-the-scope clip (1)
- Oxaliplatin (1)
- PAX3/FOXO1 (1)
- PET (1)
- Pancreas transplantation (1)
- Paracetamol (1)
- Paraneoplastic syndrome (1)
- Pathologic complete response (1)
- Pelargonium sidoides (1)
- Percutaneous ultrasound (1)
- Peroxidase (1)
- Personality disorder (1)
- Peutz–Jeghers syndrome (1)
- Pharmacodynamic (1)
- Philosophie (1)
- Physical therapist (1)
- Planning target volume (1)
- Platelets (1)
- Pneumococcal conjugate vaccine (1)
- Polyposis syndrome (1)
- Postoperative anatomy (1)
- Preoperative radiochemotherapy (1)
- Professionalism (1)
- Prophylaxis (1)
- Protein Expression (1)
- Psychopathology (1)
- Pulmonary failure (1)
- Pulmonary veins (1)
- Qualitative research (1)
- RAD001 (1)
- RIP1 (1)
- RNA interference (RNAi) (1)
- RUNX1/ETO (1)
- Radiation induced diarrhoea (1)
- Radiotherapy (1)
- Rare disease (1)
- Readmission (1)
- Rectal cancer (1)
- Rejection (1)
- Religiöses Coping (1)
- Restenosis (1)
- S1P1 receptor (1)
- SERS (1)
- SOCS (1)
- Sauerstoffpartialdruck im Gewebe (1)
- Sauerstoffversorgung (1)
- Schmerz (1)
- Schmerzminderung (1)
- Sekretion (1)
- Selenium administration in gynecologic radiation oncology (1)
- Self-expandable metal stents (1)
- Self-expandable metal stents complications (1)
- Self-management support (1)
- Signaling (1)
- Small-bowel endoscopy (1)
- Social skills training (1)
- Spectrin (1)
- Sphingolipid (1)
- Sphingosine 1-phosphate (1)
- Spondylolisthesis (1)
- Sportmedizin (1)
- Sportophthalmologie (1)
- Sportärztekongress (1)
- Stentoplasty (1)
- Study protocol (1)
- Subacute cerebellar degeneration (1)
- Subarachnoid Hemorrhage (1)
- Subfertilität (1)
- Supraventricular arrhythmias (1)
- Syk Kinase (1)
- T cell (1)
- T-cell homeostasis (1)
- T-cell niche (1)
- TEM (1)
- TEVAR (1)
- TKI (1)
- TRAIL (1)
- Tacrolimus (1)
- Tamoxifen (1)
- Temozolomide (1)
- Terminal ileitis (1)
- Thalidomide (1)
- Thoracic trauma (1)
- Thyroid Cancer Cells (1)
- Toll-like receptor (TLR) 6 (1)
- Tonsil (1)
- Toxicology (1)
- Toxins (1)
- Traumatic injury (1)
- Treatment (1)
- Tumor (1)
- Tumor obstruction (1)
- Tumor subtype (1)
- Ultrasonography (1)
- Unfallverletzung (1)
- Ungewollte Kinderlosigkeit (1)
- VEGF receptors (1)
- VIP (1)
- VPAC1 (1)
- Variceal bleeding (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Virotherapy (1)
- Vitreous samples (1)
- Western Blotting (1)
- Wilms tumor (1)
- Wissenschaft (1)
- Wunde (1)
- Wundheilung (1)
- Wundinfektion (1)
- YB-1 (1)
- Zivilisationskrankheit (1)
- active perception (1)
- acute leukemia (1)
- acute lymphoblastic leukaemia (1)
- acute myeloid leukaemia (1)
- ageing (1)
- aging (1)
- air pouch (1)
- all-ceramic (1)
- allogeneic hematopoietic stem cell transplantation (1)
- alpha peak (1)
- antifungal agents (1)
- antifungal management (1)
- antifungal prophylaxis (1)
- astrocyte (1)
- astrocytes (1)
- atherosclerosis (1)
- attention (1)
- barriers to implementation (1)
- biocompatibility (1)
- bone morphogenetic protein-2 (1)
- bone substitute material (1)
- bortezomib (1)
- brain injury (1)
- cancer (1)
- cardiovascular (1)
- cardiovascular disease (1)
- chemotherapy (1)
- childhood cancer (1)
- chromosomal translocations (1)
- chronic care (1)
- cigarette (1)
- clinical research (1)
- clinical study (1)
- clinical trials (1)
- cochlear implant (1)
- cognition (1)
- consciousness (1)
- corticomuscular coherence (CMC) (1)
- costs (1)
- crestal bone loss (1)
- critical periods (1)
- crowns (1)
- deconvolution (1)
- development (1)
- directly acting antiviral agents (1)
- distraction (1)
- dual task (1)
- endothelial (1)
- entorhinal cortex lesion (1)
- everolimus (1)
- exercise (1)
- expert review (1)
- fMRI (1)
- finger tapping (1)
- functional MRI (1)
- fungal infection (1)
- gastric (1)
- gastrointestinal (1)
- gene therapy (1)
- glutamate metabolism (1)
- granulocyte (1)
- growth factor (1)
- hand area (1)
- head and neck cancer (1)
- hematopoietic stem and progenitor cells (1)
- hemodialysis (1)
- hepatitis C virus (1)
- hereditary angioedema (1)
- hippocampal volume (1)
- homeostatic synaptic scaling (1)
- iPS (1)
- immune function (1)
- immunocytochemistry (1)
- immunology (1)
- implant (1)
- implant survival (1)
- inflammation (1)
- inhibition of DNA-binding (1)
- interferon-free (1)
- interleukin-10 (1)
- interleukin-22 (1)
- invasive fungal infection (1)
- kidney disease (1)
- lenalidomide (1)
- long-term survival (1)
- mTOR (1)
- magnetoencephalography (1)
- magnetoencephalography (MEG) (1)
- marginal bone loss (1)
- mature T-cell lymphoma (1)
- memory (1)
- metaplasticity (1)
- miRNA (1)
- miRNA-17–92 (1)
- microRNA (1)
- mild cognitive impairment (1)
- mitogen-activated protein kinase (1)
- mitomycin C (1)
- mobilization (1)
- monogenic disorders (1)
- motor control (1)
- motor task (1)
- nanoparticles (1)
- natural killer cell (1)
- necroptosis (1)
- neurobiology (1)
- neuroblastoma (1)
- neurodegeneration (1)
- neurological diseases (1)
- neurooncology (1)
- neuropsychiatric disorders (1)
- next-generation sequencing (1)
- non-invasive brain stimulation (1)
- oligodendrocyte (1)
- organotypic slice cultures (1)
- oscillations (1)
- oxidative stress (1)
- pain (1)
- peptide aptamer (PA) (1)
- perceptual organization (1)
- plasticity (1)
- posaconazole (1)
- pregnancy (1)
- pregnant (1)
- preprocedure prophylaxis (1)
- prevention (1)
- primary motor cortex (1)
- primary motor cortex (M1) (1)
- prognostic value (1)
- progranulin (1)
- prostate and breast cancer cell lines (1)
- prostate cancer (1)
- proteasome inhibitor (1)
- protein transduction (1)
- rat femur defect (1)
- receptor tyrosine kinase (1)
- reduction of pain (1)
- reinforcement learning (1)
- resting state (1)
- robotics (1)
- robustness (1)
- scaffolding proteins (1)
- sciatic nerve injury (1)
- self-management support (1)
- senescence (1)
- signal transducer and activator of transcription (1)
- signal transducer and activator of transcription 5 (Stat5) (1)
- signaling (1)
- single-sided deafness (1)
- sleep (1)
- slowing (1)
- smoking (1)
- sonic hedgehog (1)
- sparse coding (1)
- stem cell therapy (1)
- stem/progenitor cell expansion (1)
- stereo vision (1)
- structural plasticity (1)
- surgical procedures (1)
- survival rate (1)
- thalidomide (1)
- therapeutics (1)
- three point bending test (1)
- tissue blood flow (1)
- tissue oxygen partial pressure (1)
- tissue temperature (1)
- tobacco (1)
- tooth wear (1)
- toxicity (1)
- transcranial alternating current stimulation (tACS) (1)
- translocation partner genes (1)
- tricalcium phosphate (1)
- tumour-infiltrating lymphocytes (1)
- type I interferons (1)
- vascular (1)
- vergence (1)
- viral vectors (1)
- vitreous samples (1)
- wIRA (1)
- wassergefiltertes Infrarot A (1)
- water-filtered infrared-A (wIRA) (1)
- yeast-two-hybrid (Y2H) (1)
- Ätiologie (1)
- ß-tricalciumphosphate (1)
Institute
"PULS." - Ein Blog als Online-Magazin für Medizinstudierende der Goethe-Universität Frankfurt
(2013)
Im Herbst 2009 forderten Studierende im Rahmen landesweiter Proteste auch am Fachbereich Medizin/Zahnmedizin der Goethe-Universität Frankfurt mehr Transparenz und Kommunikation zu Angelegenheiten ihres Studiums. Einen innovativen Lösungsansatz, um diesen Forderungen nachzukommen, bietet eines der Web 2.0 Werkzeuge: ein auf einer Blog-Software basierendes Online-Magazin für Studierende und andere Mitglieder des Fachbereichs.
Das öffentlich zugängliche Online-Magazin "PULS." (https://newsmagazin.puls.med.uni-frankfurt.de/wp/) wird mit einer freien Blog-Software (wordpress Version 3.1.3.) realisiert und von einer Online-Redakteurin konzipiert und geschrieben. Die Beiträge entstehen nach eigenen Recherchen sowie aus Anregungen und Gesprächen mit verschiedenen Personengruppen des Fachbereichs. Die datenschutzkonforme Auswertung der Zugriffe erfolgt über eine open-source Webanalyse-Software (Piwik). Zusätzlich werden jährlich mit dem Online-Umfrage-Tool Survey Monkey die Nutzer anonym befragt.
"PULS." ist seit dem 14.02.2010 ununterbrochen online und hat seitdem 806 Beiträge (Stand: 27.11.2012) publiziert und wird von ca. 2400 Besuchern monatlich gelesen. Das Themenspektrum ist zentriert auf die Anliegen der Frankfurter Medizin- und Zahnmedizinstudierenden. Die enge Zusammenarbeit mit verschiedenen Gruppierungen des Fachbereichs – Dekanat, Studierende und Lehrende – garantiert darüber hinaus ein fachbereichs-relevantes Themenspektrum. Das Online-Magazin begleitet komplexe Projekte und Entscheidungen mit Hintergrundinformationen und kommuniziert sie verständlich. Eine jährliche Nutzer-Evaluierung zeigt eine wachsende Leserzahl und eine sehr hohe Zustimmung für das Online-Magazin, seine Inhalte und seinen Stil. Das Web 2.0-Medium "Blog" und seine web-typische Sprache entsprechen dem Medienverhalten der Zielgruppe, d.h. den Studierenden des Fachbereichs Medizin.
"PULS." hat sich als ein geeignetes und strategisches Instrument erwiesen, um größere Transparenz, mehr Kommunikation und letztendlich eine stärkere Identifikation der Studierenden mit ihrem Fachbereich voranzutreiben.
Few sequence alignment methods have been designed specifically for integral membrane proteins, even though these important proteins have distinct evolutionary and structural properties that might affect their alignments. Existing approaches typically consider membrane-related information either by using membrane-specific substitution matrices or by assigning distinct penalties for gap creation in transmembrane and non-transmembrane regions. Here, we ask whether favoring matching of predicted transmembrane segments within a standard dynamic programming algorithm can improve the accuracy of pairwise membrane protein sequence alignments. We tested various strategies using a specifically designed program called AlignMe. An updated set of homologous membrane protein structures, called HOMEP2, was used as a reference for optimizing the gap penalties. The best of the membrane-protein optimized approaches were then tested on an independent reference set of membrane protein sequence alignments from the BAliBASE collection. When secondary structure (S) matching was combined with evolutionary information (using a position-specific substitution matrix (P)), in an approach we called AlignMePS, the resultant pairwise alignments were typically among the most accurate over a broad range of sequence similarities when compared to available methods. Matching transmembrane predictions (T), in addition to evolutionary information, and secondary-structure predictions, in an approach called AlignMePST, generally reduces the accuracy of the alignments of closely-related proteins in the BAliBASE set relative to AlignMePS, but may be useful in cases of extremely distantly related proteins for which sequence information is less informative. The open source AlignMe code is available at https://sourceforge.net/projects/alignme/, and at http://www.forrestlab.org, along with an online server and the HOMEP2 data set.
Purpose: Metabolic changes upon antiangiogenic therapy of recurrent glioblastomas (rGBMs) may provide new biomarkers for treatment efficacy. Since in vitro models showed that phospholipid membrane metabolism provides specific information on tumor growth we employed in-vivo MR-spectroscopic imaging (MRSI) of human rGBMs before and under bevacizumab (BVZ) to measure concentrations of phosphocholine (PCho), phosphoethanolamine (PEth), glycerophosphocholine (GPC), and glyceroethanolamine (GPE).
Methods: 1H and 31P MRSI was prospectively performed in 32 patients with rGBMs before and under BVZ therapy at 8 weeks intervals until tumor progression. Patients were dichotomized into subjects with long overall survival (OS) (>median OS) and short OS (<median OS) survival time from BVZ-onset. Metabolite concentrations from tumor tissue and their ratios were compared to contralateral normal-appearing tissue (control).
Results: Before BVZ, 1H-detectable choline signals (total GPC and PCho) in rGBMs were elevated but significance failed after dichotomizing. For metabolite ratios obtained by 31P MRSI, the short-OS group showed higher PCho/GPC (p = 0.004) in rGBMs compared to control tissue before BVZ while PEth/GPE was elevated in rGBMs of both groups (long-OS p = 0.04; short-OS p = 0.003). Under BVZ, PCho/GPC and PEth/GPE in the tumor initially decreased (p = 0.04) but only PCho/GPC re-increased upon tumor progression (p = 0.02). Intriguingly, in normal-appearing tissue an initial PEth/GPE decrease (p = 0.047) was followed by an increase at the time of tumor progression (p = 0.031).
Conclusion: An elevated PCho/GPC ratio in the short-OS group suggests that it is a negative predictive marker for BVZ efficacy. These gliomas may represent a malignant phenotype even growing under anti-VEGF treatment. Elevated PEth/GPE may represent an in-vivo biomarker more sensitive to GBM infiltration than MRI.
In complex networks such as gene networks, traffic systems or brain circuits it is important to understand how long it takes for the different parts of the network to effectively influence one another. In the brain, for example, axonal delays between brain areas can amount to several tens of milliseconds, adding an intrinsic component to any timing-based processing of information. Inferring neural interaction delays is thus needed to interpret the information transfer revealed by any analysis of directed interactions across brain structures. However, a robust estimation of interaction delays from neural activity faces several challenges if modeling assumptions on interaction mechanisms are wrong or cannot be made. Here, we propose a robust estimator for neuronal interaction delays rooted in an information-theoretic framework, which allows a model-free exploration of interactions. In particular, we extend transfer entropy to account for delayed source-target interactions, while crucially retaining the conditioning on the embedded target state at the immediately previous time step. We prove that this particular extension is indeed guaranteed to identify interaction delays between two coupled systems and is the only relevant option in keeping with Wiener’s principle of causality. We demonstrate the performance of our approach in detecting interaction delays on finite data by numerical simulations of stochastic and deterministic processes, as well as on local field potential recordings. We also show the ability of the extended transfer entropy to detect the presence of multiple delays, as well as feedback loops. While evaluated on neuroscience data, we expect the estimator to be useful in other fields dealing with network dynamics.
Background: To compare the effect of aprotinin with the effect of lysine analogues (tranexamic acid and ε-aminocaproic acid) on early mortality in three subgroups of patients: low, intermediate and high risk of cardiac surgery.
Methods and Findings: We performed a meta-analysis of randomised controlled trials and observational with the following data sources: Medline, Cochrane Library, and reference lists of identified articles. The primary outcome measure was early (in-hospital/30-day) mortality. The secondary outcome measures were any transfusion of packed red blood cells within 24 hours after surgery, any re-operation for bleeding or massive bleeding, and acute renal dysfunction or failure within the selected cited publications, respectively.
Out of 328 search results, 31 studies (15 trials and 16 observational studies) included 33,501 patients. Early mortality was significantly increased after aprotinin vs. lysine analogues with a pooled risk ratio (95% CI) of 1.58 (1.13–2.21), p<0.001 in the low (n = 14,297) and in the intermediate risk subgroup (1.42 (1.09–1.84), p<0.001; n = 14,427), respectively. Contrarily, in the subgroup of high risk patients (n = 4,777), the risk for mortality did not differ significantly between aprotinin and lysine analogues (1.03 (0.67–1.58), p = 0.90).
Conclusion: Aprotinin may be associated with an increased risk of mortality in low and intermediate risk cardiac surgery, but presumably may has no effect on early mortality in a subgroup of high risk cardiac surgery compared to lysine analogues. Thus, decisions to re-license aprotinin in lower risk patients should critically be debated. In contrast, aprotinin might probably be beneficial in high risk cardiac surgery as it reduces risk of transfusion and bleeding complications.
The FK506-binding protein 51 (FKBP51) is an Hsp90-associated co-chaperone which regulates steroid receptors and kinases. In pancreatic cancer cell lines, FKBP51 was shown to recruit the phosphatase PHLPP to facilitate dephosphorylation of the kinase Akt, which was associated with reduced chemoresistance. Here we show that in addition to FKBP51 several other members of the FKBP family bind directly to Akt. FKBP51 can also form complexes with other AGC kinases and mapping studies revealed that FKBP51 interacts with Akt via multiple domains independent of their activation or phosphorylation status. The FKBP51-Akt1 interaction was not affected by FK506 analogs or Akt active site inhibitors, but was abolished by the allosteric Akt inhibitor VIII. None of the FKBP51 inhibitors affected AktS473 phosphorylation or downstream targets of Akt. In summary, we show that FKBP51 binds to Akt directly as well as via Hsp90. The FKBP51-Akt interaction is sensitive to the conformation of Akt1, but does not depend on the FK506-binding pocket of FKBP51. Therefore, FKBP inhibitors are unlikely to inhibit the Akt-FKBP-PHLPP network.
Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) is a rare inherited childhood neurodegenerative disease that is caused by a mutation in the gene CLN3. The function of the protein produced by the gene has remained elusive, and therefore the disease mechanism of JNCL is as of yet unknown. The disease is fatal, and no cure is currently available. We believe that simvastatin shows promise as a possible treatment. Simvastatin is well tolerated in children, and as currently no other viable, less invasive treatment for JNCL exists, at least pilot-scale clinical trials for this new off-label use of simvastatin are warranted.
The protein CLN3 has been indicated to have several different subcellular localizations and functions, but conclusive evidence about its role in cellular metabolism is lacking. It is also unclear why the mutation causes the distinct phenotype of the JNCL disease. In order to bring lucidity to the issue, we set out to identify metabolic pathways related to the phenotype of JNCL by using Multi-Epitope Ligand Cartography (MELC) and the related field of toponomics. Toponomic methods are required to process the massive amount of data generated by the MELC runs in order to extract information from them.
Our disease model of choice was the CLN3Δex7/8 knock-in mouse. To separate cause from effect, we compared embryonal wild type and mutant mouse brains to their adult counterparts. The first analyses revealed progressively abnormal Combinatorial Molecular Patterns (CMPs, an unit of toponomic data) related to cholera toxin/ganglioside 1 (Ctx/GM1), which is a membrane microdomain marker.
Cholesterol is an essential part of microdomains, so we utilized filipin staining to see if there were actual changes in cholesterol concentration and localization between healthy and diseased animals. After the disturbance in cholesterol metabolism was verified, we investigated the metabolic pathway that synthesizes cholesterol, the mevalonate pathway. Simvastatin is a drug that specifically down-regulates the mevalonate pathway. Fish oil affects lipid homeostasis and has some effects similar to those of simvastatin, and both of these drugs have previously been studied for their effects on neurodegenerative diseases. After treatment of mice with these drugs, highperformance liquid chromatography (HPLC) measurements on the brain homogenate showed a decrease in levels of farnesyl pyrophosphate (FPP) and geranyl-geranyl pyrophosphate (GGPP), products of the mevalonate pathway, confirming the effect of these drugs on the brains of the animals. Analyses of motor function of the mice further supported the notion that simvastatin had a positive effect on the condition of the diseased animals.
CMP analyses from the simvastatin treated mice showed a rescue of the Ctx/GM1 CMPs, suggesting at least a partial restoration of membrane microdomain homeostasis. Filipin staining revealed reversion of the apparent cholesterol depletion in the adult mutant mouse hippocampus by simvastatin. Interestingly, an additional effect of the treatment was found: simvastatin also affected glutamate receptor homeostasis, especially as regarding to N-methyl-D-aspartate (NMDA) and alphaamino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptors. This finding suggested that excitotoxicity could be a part of the disease process, and pointed towards glutamate receptors as possible therapy targets. This is in line with previous studies that have shown that attenuation of AMPA receptors and L voltage-dependent channels improve the phenotype of a JNCL mouse and cell model, respectively.
Simvastatin mediates many of its effects via downregulation of the mevalonate pathway products, such as isoprenoids and cholesterol. However, simvastatin also has multiple pleiotropic effects that include suppression of excitotoxicity and granting neuroprotection. It is apparent that simvastatin treatment has a positive effect on JNCL mice, but if its effects are mediated via cholesterol (and membrane microdomains), isoprenoids (and isoprenylated proteins) or via a fully cholesterol independent mechanism remains to be solved.
In this study we have shown that with the MELC method and toponomics it is possible to approach rare diseases with confounded disease mechanisms with a hypothesis-free approach, to identify possible drug targets, and to monitor the effects of the drugs on treated individuals. This should open up a new avenue in the research of the many diseases that so far have avoided all attempts at discerning their nature.
Introduction: Acute kidney injury (AKI) can evolve quickly and clinical measures of function often fail to detect AKI at a time when interventions are likely to provide benefit. Identifying early markers of kidney damage has been difficult due to the complex nature of human AKI, in which multiple etiologies exist. The objective of this study was to identify and validate novel biomarkers of AKI.
Methods: We performed two multicenter observational studies in critically ill patients at risk for AKI - discovery and validation. The top two markers from discovery were validated in a second study (Sapphire) and compared to a number of previously described biomarkers. In the discovery phase, we enrolled 522 adults in three distinct cohorts including patients with sepsis, shock, major surgery, and trauma and examined over 300 markers. In the Sapphire validation study, we enrolled 744 adult subjects with critical illness and without evidence of AKI at enrollment; the final analysis cohort was a heterogeneous sample of 728 critically ill patients. The primary endpoint was moderate to severe AKI (KDIGO stage 2 to 3) within 12 hours of sample collection.
Results: Moderate to severe AKI occurred in 14% of Sapphire subjects. The two top biomarkers from discovery were validated. Urine insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2), both inducers of G1 cell cycle arrest, a key mechanism implicated in AKI, together demonstrated an AUC of 0.80 (0.76 and 0.79 alone). Urine [TIMP-2].[IGFBP7] was significantly superior to all previously described markers of AKI (P <0.002), none of which achieved an AUC >0.72. Furthermore, [TIMP-2].[IGFBP7] significantly improved risk stratification when added to a nine-variable clinical model when analyzed using Cox proportional hazards model, generalized estimating equation, integrated discrimination improvement or net reclassification improvement. Finally, in sensitivity analyses [TIMP-2].[IGFBP7] remained significant and superior to all other markers regardless of changes in reference creatinine method.
Conclusions: Two novel markers for AKI have been identified and validated in independent multicenter cohorts. Both markers are superior to existing markers, provide additional information over clinical variables and add mechanistic insight into AKI. Trial registration: ClinicalTrials.gov number NCT01209169.
Background: The students' perception of working conditions in hospitals hasn't been subject of research in Germany so far. However the perception plays an important role talking about the sustainability of working conditions. The iCept Study wants to examine the perception of medical students compared to the perception of practicing physicians.
Methods: The perception will be investigated with a redesigned questionnaire based upon two established and validated questionnaires. The two samples built for this study (students and physician) will be chosen from members of the labor union Marburger Bund. The iCept-Study is designed as an anonymized online-survey.
Discussion: The iCept-Study is thought to be the basis of ongoing further investigations regarding the perception of working conditions in hospitals. The results shall serve the facilitation of improving working conditions.
Im Rahmen einer prospektiven Kohortenstudie wurde in der vorliegenden Arbeit die Epidemiologie und Ätiologie von Fieber während chemotherapiebedingter Neutropenie bei Patienten mit hämatologischen Neoplasien untersucht. Das diagnostische und therapeutische Vorgehen wurde beschrieben und die Übereinstimmung mit den Vorgaben einer hausinternen Leitlinie wurde evaluiert und der Verbrauch an antimikrobiellen Substanzen dokumentiert. Febrile Episoden konnten in 74% der Neutropenieepisoden dokumentiert werden; in 51% der Neutropenieepisoden kam es zu persistierendem Fieber ≥ 3 Tage. Eine dem Fieber zugrunde liegende Infektion wurde in 55% der Chemotherapiezyklen (Neutropeniedauer Median 16 Tage) mittels klinischer, apparativer und mikrobiologischer Diagnostik gefunden. Die häufigsten infektiösen Komplikationen waren Enteritiden mit Nachweis von C. difficile (11%), Enteritiden ohne Nachweis von C. difficile (29%), Pneumonien mit pilztypischen Infiltraten (12%) und Pneumonien mit unspezifischen Infiltraten (11%), sowie mikrobiologisch bestätigte Septikämien (18%). Im Vergleich zu Angaben in der Literatur wurde FUO in der vorliegenden Untersuchung häufiger diagnostiziert (11,8 Tage pro 1000 Patiententage vs. 8,2 Tage pro 1000 Patiententage). Die Gesamtmortalität des Kollektivs lag bei 7%. Die häufigste Todesursache war der septische Schock (8 von 5 Patienten; 63%), welcher sich auf dem Boden einer gramnegativen Septikämie mit multiresistenten Keimen entwickelt hatte (3 von 5 Septikämien; 60%). Die Mortalitätsrate war ähnlich hoch wie im Literaturvergleich bei Studien mit akuten myeloischen Leukämien. Prognoserelevante Faktoren, welche im Rahmen der vorliegenden Studie evaluiert wurden, sind durch schwer therapierbare Grunderkrankungen hervorgerufene prolongierte Neutropeniezeiten, sowie infektiöse Komplikationen, vor allem bei Nachweis multiresistenter Erreger.
Die Compliance bezüglich des diagnostischen und therapeutischen Vorgehens bei persistierendem Fieber betrug in der vorliegenden Arbeit zwischen 47% und 82%. Die Compliance mit den in der Leitlinie vorgeschlagenen antimikrobiellen prophylaktischen und initialen empirischen Therapien lag zwischen 83% und 85%. Der Gesamtverbrauch an antibiotischen und antimykotischen Substanzen war in der vorliegenden Studie höher als im Literaturvergleich (1647 DDD vs. 1140 DDD und 650 DDD vs. 430 DDD). Dabei fällt insbesondere der hohe Verbrauch an Reservemedikamenten gegen grampositive Bakterien auf. Allerdings fehlen aktuelle Vergleichsdaten vergleichbarer Patientenkollektive.
Bezüglich der Optimierung der diagnostischen Maßnahmen ist vor allem die Erhöhung der Sensitivität der Bronchoalveolären Lavage bei Pilzinfektionen, rechtzeitig und regelmäßig durchgeführte Surveillanceabstriche bei febriler Neutropenie, sowie die Diskussion der diagnostischen Ergebnisse und des weiteren therapeutischen Vorgehens mit infektiologischen Experten zu fordern. Patienten mit persistierendem Fieber - vor allem bei positivem Blutkulturnachweis - sollten, aufgrund des positiven prädiktiven Wertes erregerpositiver Blutkulturen für die Notwendigkeit einer intensivmedizinischen Betreuung und einer erhöhten Mortalität, Anlass sein, diagnostische und therapeutische Maßnahmen zu verbessern. Ziel ist es, durch verstärkten Einsatz diagnostischer Maßnahmen und Diskussion mikrobiologischer Befunde im Einzelfall, Reservesubstanzen seltener einzusetzen, gegebenenfalls Breitspektrum-Antibiotika oder ihre Kombinationen zu deeskalieren und somit die Kolonisation mit resistenten Erregern positiv zu beeinflussen, sowie das Ansprechen auf antimikrobielle Therapien zu optimieren.
Die Teilnahme an multizentrischen Surveillancestudien zur Inzidenzerfassung wichtiger, eindeutig definierter neutropener nosokomialer Infektionen wie radiologisch detektierter Pneumonien, mikrobiologisch bestätigter Septikämien und C. difficilepositiver Enteritiden, sowie zur Generierung von Antiinfektivaverbrauchszahlen, könnte helfen, die Beratung und Entscheidungsfindung am Krankenbett zu unterstützen. Auch könnten in diesem Rahmen Zahlen generiert werden, welche bisher zum Vergleich fehlten.
Die vorliegende Arbeit versteht sich im Rahmen der Erfassung von Ätiologie, Diagnostik und antimikrobieller Therapien bei febriler Neutropenie als Teil eines solchen Surveillanceprogrammes und hat somit eine Grundlagen für zukünftige Datenerhebungen geliefert.
kurz und kn@pp news : Nr. 27
(2013)
In the absence of apparent mutations, alteration of gene expression patterns represents the key mechanism by which normal cells evolve to cancer cells.
Gene expression is tightly regulated by posttranscriptional processes. Within this context, RNA-binding proteins (RBPs) represent fundamental factors, since they control mechanisms, such as mRNA-stabilization, -translation and -degradation. Human antigen R (HuR) was among the first RBPs that have been directly associated to carcinogenesis. HuR modulates the stability and translation of mRNAs which encode proteins facilitating various ‘hallmarks of cancer’, namely proliferation, evasion of growth suppression, angiogenesis, cell death resistance, invasion and metastasis. Furthermore, it is well established that tumor-promoting inflammation contributes to tumorigenesis. In this process, monocytes are attracted to the site of the tumor and educated towards a tumor-promoting macrophage phenotype. While HuR has been extensively studied in various tumor cell types, little is known about HuR in hepatocellular carcinoma (HCC). Thus, the aim of my work was to characterize the contribution of HuR to the development of cancer characteristics in HCC. I was particularly interested to investigate if HuR facilitates tumor-promoting inflammation, since a role for HuR has not been described in this context. To this end, I depleted HuR in HepG2 cells (HuR k/d) and used a co-culture model of HepG2 tumor spheroids and infiltrating monocytes to study the impact of HuR on the tumor microenvironment. I could show that depletion of HuR resulted in the reduction of cell numbers. Additionally, the expression of proliferation marker KI-67 and proto-oncogene c-Myc was reduced, supporting a proliferative role of HuR. Furthermore, exposure to cytotoxic staurosporine elevated apoptosis in HuR k/d cells compared to control cells. Concomitantly, the expression of the anti-apoptotic mediator B-cell lymphoma protein-2 (Bcl-2) was markedly reduced in the HuR k/d cells, pointing to an involvement of HuR in cell survival processes.
Accordingly, a pro-survival function of HuR was also observed in tumor spheroids, since HuR k/d spheroids exhibited a larger necrotic core region at earlier time points and showed elevated numbers of dead cells compared to control (Ctr.) spheroids. Interestingly, HuR k/d spheroids isplayed reduced numbers of infiltrated macrophages, suggesting that HuR contributes to a tumor-promoting, inflammatory microenvironment by recruiting monocytes/macrophages to the tumor site. Aiming at identifying HuR-regulated factors responsible for the recruitment of monocytes, I found reduced levels of the chemokine interleukin 8 (IL-8) in supernatants of HuR k/d spheroids, supporting a critical involvement of HuR in the chemoattraction of monocytes. Analyzing supernatants of co-cultures of macrophages and HuR k/d or Ctr. spheroids revealed additional differences in chemokine secretion patterns. Interestingly, protein levels of many chemokines were elevated in co-cultures of HuR k/d spheroids compared to control co-cultures. Albeit enhanced chemokine secretion was observed, less monocytes are recruited into HuR k/d spheroids, further underlining the necessity of HuR in cancer related monocyte/macrophage attraction and infiltration. Differences between chemokine profiles of mono- and co-cultured spheroids could be attributable to changes in spheroid-derived chemokines as a result of the crosstalk with the immune cells. Provided the chemokines originate from monocytes/macrophages, the different secretion patterns suggest that HuR contributes to the modulation of the functional phenotype of infiltrated macrophages, since the tumorenvironment is critically involved in the shaping of macrophage phenotypes. Regions of low-oxygen (hypoxia) represent another critical feature of tumors. Therefore, I next analyzed the impact of HuR on the hypoxic response. Loss of HuR attenuated hypoxia-inducible factor (HIF) 2α expression after exposure to hypoxia, while HIF-1α protein levels remained unaltered. Considering previous results of our group, showing that HIF-2α depletion (HIF-2α k/d) resulted in the enhanced expression of HIF-1α protein, I aimed to determine the involvement of HuR in the compensatory upregulation of HIF-1α protein in HIF-2α k/d cells. I could demonstrate that not only total HuR protein levels, but specifically cytoplasmic HuR was elevated in HIF-2α depleted cells pointing to enhanced HuR activity. Silencing HuR in HIF-2α deficient cells attenuated enhanced HIF-1α protein expression, thus confirming a direct role of HuR in the compensatory upregulation of HIF-1α. This as also reflected on HIF-1α target gene expression. I further investigated the mechanism underlying the compensatory HIF-1α expression in HIF-2α deficient cells. Analyzing HIF-1α mRNA expression, I excluded enhanced HIF1-α transcription and stability to account for elevated HIF-1α expression in HIF-2α k/d cells. HIF-1α promoter activity assays confirmed the mRNA data. Furthermore, HIF-1α protein half-life was not elevated in HIF-2α k/d cells compared to control cells, indicating that HIF-1α protein stability is not altered in HIF-2α k/d cells. Analysis of the association of HIF-1α with the translational machinery using polysomal fractionation finally revealed an increased istribution of HIF-1α mRNA in the heavier polysomal fractions in HIF-2α k/d cells compared to control cells. Since augmented ribosome occupancy is an indicator for more efficient translation, I propose enhanced HIF-1α translation as underlying principle of the compensatory increase in HIF-1α protein levels in HIF-2α k/d cells. In summary, my results demonstrate that HuR is critical for the development of cancer characteristics in HCC. Future work analyzing the impact of HuR on tumor-promoting inflammation, specifically macrophage attraction and activation could provide new trategies to inhibit macrophage-driven tumor progression. Furthermore, I provide evidence that HuR contributes to the hypoxic response by regulating the expression of HIF-1α and HIF-2α. Targeting single HIF-isoforms for tumor therapy should be carefully considered, because of their compensatory regulation when one α-subunit is depleted. Thus, therapeutic strategies targeting factors such as HuR that control both α-subunits and at the same time prevent compensation might be more promising.
Since most anticancer therapies including immunotherapy trigger programmed cell death in cancer cells, defective cell death programs can lead to treatment resistance and tumor immune escape. Therefore, evasion of programmed cell death may provide one possible explanation as to why cancer immunotherapy has so far only shown modest clinical benefits for children with cancer. A better understanding of the molecular mechanisms that regulate sensitivity and resistance to programmed cell death is expected to open new perspectives for the development of novel experimental treatment strategies to enhance the efficacy of cancer immunotherapy in the future.
Cataract surgery is one of the oldest and the most frequent outpatient clinic operations in medicine performed worldwide. The clouded human crystalline lens is replaced by an artificial intraocular lens implanted into the capsular bag. During the last six decades, cataract surgery has undergone rapid development from a traumatic, manual surgical procedure with implantation of a simple lens to a minimally invasive intervention increasingly assisted by high technology and a broad variety of implants customized for each patient’s individual requirements. This review discusses the major advances in this field and focuses on the main challenge remaining – the treatment of presbyopia. The demand for correction of presbyopia is increasing, reflecting the global growth of the ageing population. Pearls and pitfalls of currently applied methods to correct presbyopia and different approaches under investigation, both in lens implant technology and in surgical technology, are discussed.
Introduction. Cancellous bone is frequently used for filling bone defects in a clinical setting. It provides favourable conditions for regenerative cells such as MSC and early EPC. The combination of MSC and EPC results in superior bone healing in experimental bone healing models. Materials and Methods. We investigated the influence of osteogenic culture conditions on the endothelial properties of early EPC and the osteogenic properties of MSC when cocultured on cancellous bone. Additionally, cell adhesion, metabolic activity, and differentiation were assessed 2, 6, and 10 days after seeding.
Results. The number of adhering EPC and MSC decreased over time; however the cells remained metabolically active over the 10-day measurement period. In spite of a decline of lineage specific markers, cells maintained their differentiation to a reduced level. Osteogenic stimulation of EPC caused a decline but not abolishment of endothelial characteristics and did not induce osteogenic gene expression. Osteogenic stimulation of MSC significantly increased their metabolic activity whereas collagen-1α and alkaline phosphatase gene expressions declined. When cocultured with EPC, MSC’s collagen-1α gene expression increased significantly. Conclusion. EPC and MSC can be cocultured in vitro on cancellous bone under osteogenic conditions, and coculturing EPC with MSC stabilizes the latter’s collagen-1α gene expression.
While necroptosis has for long been viewed as an accidental mode of cell death triggered by physical or chemical damage, it has become clear over the last years that necroptosis can also represent a programmed form of cell death in mammalian cells. Key discoveries in the field of cell death research, including the identification of critical components of the necroptotic machinery, led to a revised concept of cell death signaling programs. Several regulatory check and balances are in place in order to ensure that necroptosis is tightly controlled according to environmental cues and cellular needs. This network of regulatory mechanisms includes metabolic pathways, especially those linked to mitochondrial signaling events. A better understanding of these signal transduction mechanisms will likely contribute to open new avenues to exploit our knowledge on the regulation of necroptosis signaling for therapeutic application in the treatment of human diseases.
CSF and serum biomarkers focusing on cerebral vasospasm and ischemia after subarachnoid hemorrhage
(2013)
Delayed cerebral vasospasm (CVS) and delayed cerebral ischemia (DCI) remain severe complications after subarachnoid hemorrhage (SAH). Although focal changes in cerebral metabolism indicating ischemia are detectable by microdialysis, routinely used biomarkers are missing. We therefore sought to evaluate a panel of possible global markers in serum and cerebrospinal fluid (CSF) of patients after SAH.
CSF and serum of SAH patients were analyzed retrospectively. In CSF, levels of inhibitory, excitatory, and structural amino acids were detected by high-performance liquid chromatography (HPLC). In serum, neuron-specific enolase (NSE) and S100B level were measured and examined in conjunction with CVS and DCI. CVS was detected by arteriography, and ischemic lesions were assessed by computed tomography (CT) scans.
All CSF amino acids were altered after SAH. CSF glutamate, glutamine, glycine, and histidine were significantly correlated with arteriographic CVS. CSF glutamate and serum S100B were significantly correlated with ischemic events after SAH; however, NSE did not correlate neither with ischemia nor with vasospasm. Glutamate, glutamine, glycine, and histidine might be used in CSF as markers for CVS. Glutamate also indicates ischemia. Serum S100B, but not NSE, is a suitable marker for ischemia. These results need to be validated in larger prospective cohorts.
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric junction.
Methods: Patients received neoadjuvant radiotherapy (50.4 Gy) together with weekly docetaxel (20 mg/m2 at dose level (DL) 1 and 2, 25 mg/m2 at DL 3) and oxaliplatin (40 mg/m2 at DL 1, 50 mg/m2 at DL 2 and 3) over 5 weeks. The primary endpoint was the DLT and the MTD of the RCT regimen. Secondary endpoints included overall response rate (ORR) and progression-free survival (PFS).
Results: A total of 24 patients were included. Four patients were treated at DL 1, 13 patients at DL 2 and 7 patients at DL 3. The MTD of the RCT was considered DL 2 with docetaxel 20 mg/m2 and oxaliplatin 50 mg/m2. Objective response (CR/PR) was observed in 32% (7/22) of patients. Eighteen patients (75%) underwent surgery after RCT. The median PFS for all patients (n = 24) was 6.5 months. The median overall survival for all patients (n = 24) was 16.3 months. Patients treated at DL 2 had a median overall survival of 29.5 months.
Conclusion: Neoadjuvant RCT with docetaxel 20 mg/m2 and oxaliplatin 50 mg/m2 was effective and showed a good toxicity profile. Future studies should consider the addition of targeted therapies to current neoadjuvant therapy regimens to further improve the outcome of patients with advanced cancer of the oesophagogastric junction.
Trial Registration: NCT00374985
Background: Interferon and ribavirin therapy for chronic hepatitis C virus (HCV) infection yields sustained virological response (SVR) rates of 50–80%. Several factors such as non-1 genotype, beneficial IL28B genetic variants, low baseline IP-10, and the functionality of HCV-specific T cells predict SVR. With the pending introduction of new therapies for HCV entailing very rapid clearance of plasma HCV RNA, the importance of baseline biomarkers likely will increase in order to tailor therapy. CD26 (DPPIV) truncates the chemokine IP-10 into a shorter antagonistic form, and this truncation of IP-10 has been suggested to influence treatment outcome in patients with chronic HCV infection patients. In addition, previous reports have shown CD26 to be a co-stimulator for T cells. The aim of the present study was to assess the utility of CD26 as a biomarker for treatment outcome in chronic hepatitis C and to define its association with HCV-specific T cells.
Methods: Baseline plasma from 153 genotype 1 and 58 genotype 2/3 infected patients enrolled in an international multicenter phase III trial (DITTO-HCV) and 36 genotype 1 infected patients participating in a Swedish trial (TTG1) were evaluated regarding baseline soluble CD26 (sCD26) and the functionality of HCV-specific CD8+ T cells.
Results: Genotype 1 infected patients achieving SVR in the DITTO (P = 0.002) and the TTG1 (P = 0.02) studies had lower pretreatment sCD26 concentrations compared with non-SVR patients. Sixty-five percent of patients with sCD26 concentrations below 600 ng/mL achieved SVR compared with 39% of the patients with sCD26 exceeding 600 ng/mL (P = 0.01). Patients with sCD26 concentrations below 600 ng/mL had significantly higher frequencies of HCV-specific CD8+ T cells (P = 0.02).
Conclusions: Low baseline systemic concentrations of sCD26 predict favorable treatment outcome in chronic HCV infection and may be associated with higher blood counts of HCV-specific CD8+ T cells.
Apoptosis represents one of the most important forms of cell death in higher organisms and is typically dysregulated in human cancers, including pediatric tumors. This implies that ineffective engagement of cell death programs can contribute to tumor formation as well as tumor progression. In addition, the majority of cytotoxic therapeutic principles rely on the activation of cell death signaling pathways in cancer cells. Blockade of signaling networks that lead to cell death can therefore confer treatment resistance. A variety of genetic and epigenetic events as well as dysfunctional regulation of signaling networks have been identified as underlying causes of cell death resistance in childhood malignancies. Apoptosis pathways can be therapeutically exploited by enhancing proapoptotic signals or by neutralizing antiapoptotic programs. The challenge in the coming years will be to successfully transfer this knowledge into the development of innovative treatment approaches for children with cancer.